机构:
Univ Arkansas Med Sci, Dept Ophthalmol, Jones Eye Inst, Little Rock, AR 72205 USAUniv Arkansas Med Sci, Dept Ophthalmol, Jones Eye Inst, Little Rock, AR 72205 USA
Bora, Nalini S.
[1
]
Jha, Purushottam
论文数: 0引用数: 0
h-index: 0
机构:
Univ Arkansas Med Sci, Dept Ophthalmol, Jones Eye Inst, Little Rock, AR 72205 USAUniv Arkansas Med Sci, Dept Ophthalmol, Jones Eye Inst, Little Rock, AR 72205 USA
Jha, Purushottam
[1
]
Bora, Puran S.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Arkansas Med Sci, Dept Ophthalmol, Jones Eye Inst, Little Rock, AR 72205 USAUniv Arkansas Med Sci, Dept Ophthalmol, Jones Eye Inst, Little Rock, AR 72205 USA
Bora, Puran S.
[1
]
机构:
[1] Univ Arkansas Med Sci, Dept Ophthalmol, Jones Eye Inst, Little Rock, AR 72205 USA
Functionally active complement system and complement regulatory proteins are present in the normal human and rodent eye. Complement activation and its regulation by ocular complement regulatory proteins contribute to the pathology of various ocular diseases including keratitis, uveitis and age-related macular degeneration. Furthermore, a strong relationship between age-related macular degeneration and polymorphism in the genes of certain complement components/complement regulatory proteins is now well established. Recombinant forms of the naturally occurring complement regulatory proteins have been exploited in the animal models for treatment of these ocular diseases. It is hoped that in the future recombinant complement regulatory proteins will be used as novel therapeutic agents in the clinic for the treatment of keratitis, uveitis, and age-related macular degeneration.
引用
收藏
页码:85 / 95
页数:11
相关论文
共 99 条
[81]
Prendergast RA, 1998, INVEST OPHTH VIS SCI, V39, P754